[1]
|
Haferkamp, A., Dörsam, J., Resnick, N.M., Yalla, S.V. and Elbadawi, A. (2003) Structural Basis of Neurogenic Bladder Dysfunction. II. Myogenic Basis of Detrusor Hyperreflexia. The Journal of Urology, 169, 547-554. https://doi.org/10.1016/S0022-5347(05)63951-1
|
[2]
|
Lee, W.C., Wu, H.P., Tai, T.Y., Yu, H.J. and Chiang, P.H. (2009) Investigation of Urodynamic Characteristics and Bladder Sensory Function in the Early Stages of Diabetic Bladder Dysfunction in Women with Type 2 Diabetes. The Journal of Urology, 181, 198-203. https://doi.org/10.1016/j.juro.2008.09.021
|
[3]
|
Liao, C.H., Chung, S.D. and Kuo, H.C. (2011) Diagnostic Value of International Prostate Symptom Score Voiding-to-Storage Subscore Ratio in Male Lower Urinary Tract Symptoms. International Journal of Clinical Practice, 65, 552-558. https://doi.org/10.1111/j.1742-1241.2011.02638.x
|
[4]
|
Yamaguchi, O., Marui, E., Kakizaki, H., Itoh, N., Yokota, T., Okada, H., Ishizuka, O., Ozono, S., Gotoh, M., Sugiyama, T., Seki, N., Yoshida, M. and Japanese Solifenacin Study Group (2007) Randomized, Double-Blind, Placebo- and Propiverine-Controlled Trial of the Once-Daily Antimuscarinic Agent Solifenacin in Japanese Patients with Overactive Bladder. BJU International, 100, 579-587. https://doi.org/10.1111/j.1464-410X.2007.07031.x
|
[5]
|
Cardozo, L., Hessdörfer, E., Milani, R., Arañó, P., Dewilde, L., Slack, M., Drogendijk, T., Wright, M., Bolodeoku, J. and SUNRISE Study Group (2008) Solifenacin in the Treatment of Urgency and Other Symptoms of Overactive Bladder: Results from a Randomized, Double Blind, Placebo-Controlled, Rising-Dose Trial. BJU International, 102, 1120-1127. https://doi.org/10.1111/j.1464-410X.2008.07939.x
|
[6]
|
Bougas, D.A., Mitsogiannis, I.C., Mitropoulos, D.N., Kollaitis, G.C., Serafetinides, E.N. and Giannopoulos, A.M. (2004) Clinical Efficacy of Distigmine Bromide in the Treatment of Patients with Underactive Detrusor. International Urology and Nephrology, 36, 507-512. https://doi.org/10.1007/s11255-004-0847-8
|
[7]
|
Yamanishi, T., Yasuda, K., Kamai, T., Tsujii, T., Sakakibara, R., Uchiyama, T. and Yoshida, K. (2004) Combination of a Cholinergic Drug and an Alpha-Blocker Is More Effective than Monotherapy for the Treatment of Voiding Difficulty in Patients with Underactive Detrusor. International Journal of Urology, 11, 88-96. https://doi.org/10.1111/j.1442-2042.2004.00753.x
|
[8]
|
Chapple, C.R., Herschorn, S., Abrams, P., Wang, J.T., Brodsky, M. and Guan, Z. (2010) Efficacy and Safety of Tolterodine Extended-Release in Men with Overactive Bladder Symptoms Treated with an α-Blocker: Effect of Baseline Prostate-Specific Antigen Concentration. BJU International, 106, 1332-1338. https://doi.org/10.1111/j.1464-410X.2010.09359.x
|
[9]
|
Sugaya, K., Nishijima, S., Kadekawa, K., Ashitomi, K. and Yamamoto, H. (2012) Effect of Distigmine Combined with Propiverine on Bladder Activity in Rats with Spinal Cord Injury. International Journal of Urology, 19, 480-483. https://doi.org/10.1111/j.1442-2042.2011.02953.x
|
[10]
|
Chapple, C.R., Cardozo, L., Nitti, V.W., Siddiqui, E. and Michel, M.C. (2014) Mirabegron in Overactive Bladder: A Review of Efficacy, Safety, and Tolerability. Neurourology and Urodynamics, 33, 17-30. https://doi.org/10.1002/nau.22505
|
[11]
|
Yamaguchi, O., Marui, E., Igawa, Y., Takeda, M., Nishizawa, O., Ikeda, Y. and Ohkawa, S. (2015) Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Lower Urinary Tract Symptoms, 7, 84-92. https://doi.org/10.1111/luts.12053
|
[12]
|
Michel, M.C. (2011) β-Adrenergic Receptor Subtypes in the Urinary Tract. Handbook of Experimental Pharmacology, 202, 307-318. https://doi.org/10.1007/978-3-642-16499-6_15
|
[13]
|
Alexandre, E.C., Kiguti, L.R., Calmasini, F.B., Silva, F.H., da Silva, K.P., Ferreira, R., Ribeiro, C.A., Mónica, F.Z., Pupo, A.S. and Antunes, E. (2016) Mirabegron Relaxes Urethral Smooth Muscle by a Dual Mechanism Involving β3-Adrenoceptor Activation and α1-Adrenoceptor Blockade. British Journal of Pharmacology, 173, 415-428. https://doi.org/10.1111/bph.13367
|
[14]
|
Miyazaki, N., Yamaguchi, O., Nomiya, M., Aikawa, K. and Kimura, J. (2016) Preventive Effect of Hydrogen Water on the Development of Detrusor Overactivity in a Rat Model of Bladder Outlet Obstruction. The Journal of Urology, 195, 780-787. https://doi.org/10.1016/j.juro.2015.10.117
|
[15]
|
Ohtake, A., Saitoh, C., Yuyama, H., Ukai, M., Okutsu, H., Noguchi, Y., Hatanaka, T., Suzuki, M., Sato, S., Sasamata, M. and Miyata, K. (2007) Pharmacological Characterization of a New Antimuscarinic Agent, Solifenacin Succinate, in Comparison with Other Antimuscarinic Agents. Biological and Pharmaceutical Bulletin, 30, 54-58. https://doi.org/10.1248/bpb.30.54
|
[16]
|
Suzuki, M., Ohtake, A., Yoshino, T., Yuyama, H., Hayashi, A., Ukai, M., Okutsu, H., Noguchi, Y., Sato, S. and Sasamata, M. (2005) Effects of Solifenacin Succinate (YM905) on Detrusor Overactivity in Conscious Cerebral Infarcted Rats. European Journal of Pharmacology, 512, 61-66. https://doi.org/10.1016/j.ejphar.2005.02.023
|
[17]
|
Yoshida, M., Masunaga, K., Nagata, T., Maeda, Y., Miyamoto, Y., Kudoh, J. and Homma, Y. (2009) Attenuation of Non-Neuronal Adenosine Triphosphate Release from Human Bladder Mucosa by Antimuscarinic Agents. Lower Urinary Tract Symptoms, 1, 88-92. https://doi.org/10.1111/j.1757-5672.2009.00049.x
|
[18]
|
Ohtake, A., Sato, S., Sasamata, M. and Miyata, K. (2010) The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urgency Episodes. Journal of Pharmacological Sciences, 112, 135-141. https://doi.org/10.1254/jphs.09R13FM
|
[19]
|
Takasu, T., Ukai, M., Sato, S., Matsui, T., Nagase, I., Maruyama, T., Sasamata, M., Miyata, K., Uchida, H. and Yamaguchi, O. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4-(2-(2-hydroxy-2-phenyltheyl)amino)ethyl)acetanilide (YM178), a Novel Selective Beta 3-Adrenoceptor Agonist on Bladder Function. Journal of Pharmacology and Experimental Therapeutics, 321, 642-647. https://doi.org/10.1124/jpet.106.115840
|
[20]
|
Aizawa, N., Homma, Y. and Igawa, Y. (2012) Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared with the Effects of Oxybutynin. European Urology, 62, 1165-1173. https://doi.org/10.1016/j.eururo.2012.08.056
|
[21]
|
Sacco, E. and Bientinesi, R. (2012) Mirabegron: A Review of Recent Data and Its Prospects in the Management of Overactive Bladder. Therapeutic Advances in Urology, 4, 315-324. https://doi.org/10.1177/1756287212457114
|
[22]
|
Takeda, M., Obara, K., Mizusawa, T., Tomita, Y., Arai, K., Tsutsui, T., Hatano, A., Takahashi, K. and Nomura, S. (1999) Evidence for beta-3-AR Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological Methods. Journal of Pharmacology and Experimental Therapeutics, 288, 1367-1373.
|
[23]
|
Hatanaka, T., Ukai, M., Watanabe, M., Someya, A., Ohtake, A., Suzuki, M., Ueshima, K., Sato, S. and Kaku, S. (2013) Effect of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Bladder Function during Storage Phase in Rats. Naunyn-Schmiedeberg’s Archives of Pharmacology, 386, 71-78. https://doi.org/10.1007/s00210-012-0814-3
|
[24]
|
Woods, M., Carson, N., Norton, N., Sheldon, J. and Argentieri, T. (2001) Efficacy of the Beta-3-adrenergic Receptor Agonist CL-316243 on Experimental Bladder Hyperreflexia and Detrusor Instability in the Rat. The Journal of Urology, 166, 1142-1147. https://doi.org/10.1016/S0022-5347(05)65936-8
|
[25]
|
Sekiya, S., Michikawa, H., Tanaka, Y. and Koike, K. (2006) Effects of Distigmine on the Intraurethral Pressure of Anesthetized Guinea-Pigs. Pharmacometrics, 71, 19-27.
|
[26]
|
Sekiya, S., Ookawa, N., Horinouchi, T., Tanaka, Y. and Koike, K. (2006) Effects of Distigmine, a Long-Acting Cholinesterase Inhibitor, on Urinary Bladder Contractile. Functions Assessed by Using Cystometry Method in Anesthetized Guinea-Pigs. Pharmacometrics, 70, 29-34.
|
[27]
|
Wöllner, J. and Pannek, J. (2016) Initial Experience with the Treatment of Neurogenic Detrusor Overactivity with a New β-3 Agonist (Mirabegron) in Patients with Spinal Cord Injury. Spinal Cord, 54, 78-82. https://doi.org/10.1038/sc.2015.195
|
[28]
|
Lee, C.L. and Kuo, H.C. (2019) Efficacy and Safety of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Detrusor Hyperactivity and Impaired Contractility. Lower Urinary Tract Symptoms, 11, O93-O97. https://doi.org/10.1111/luts.12224
|